Birelentinib clinical trials
Also written DZD8586.
How each study uses birelentinib is sorted by a rule, right about nine times in ten. Readers can ask us to read every study one by one.Ask us to read each study
Get an email when these change. Save the birelentinib studies recruiting or about to start — once a week, free: studies that open, close, add sites or post results.
See an example email
Example · made-up studies
Breast cancer · Recruiting: 2 came in, 3 changed
What changed in your alerts, Oct 31 – Nov 6:
A study of drug A after surgery for early breast cancer
Came in · now Recruiting
Drug B with hormone therapy in advanced breast cancer
Changed
· Sites: 4 added, including Seoul and Busan
· Enrollment: 300 → 450 participants
Exercise during chemotherapy
Now Active, not recruiting
One email a week for all your alerts. Stop any time.
Approvals
The first approval found in each region, with its record
- United States
- Not in FDA's approval records
- European Union
- Not in EMA's list of EU-wide authorizations
From FDA's Drugs@FDA and Purple Book (through openFDA) and the European Medicines Agency, files of Sept 2026 and 27 Oct 2026. National approvals in Europe and other countries are not included. How this is worked out
Studies by the year they started
12 studies that test it; most in 2026 (4)
| Year | Studies |
|---|---|
| 2021 | 1 |
| 2022 | 1 |
| 2023 | 1 |
| 2024 | 2 |
| 2025 | 3 |
| 2026 | 4 |
By phase
A phase 1/2 study counts in both.
What it is tested for
Each study’s main condition, where its own words name it, so a study counts once.
Who runs them
Industry 12 · Other 0
Dizal Pharmaceuticals (11) · Dizal (Jiangsu) Pharmaceutical Co., Ltd. (1)
Often tested with
Tested in the same studies.
R-CHOP Regimen (1) · R-GemOx Regimen (1)
Related medicines
As reviewed, each with the page that says it.
Coming up
From the study records. Dates are the sponsors’ own estimates and often move.
Reaching primary completion within a year · 3
Studies that test birelentinib.
- Nov 2026Assessing the Effect of a Proton Pump Inhibitor on the Pharmacokinetics of DZD8586 in Healthy Participants (TAI-SHAN21)Phase 1 · Dizal Pharmaceuticals
- Jul 2027A Study of DZD8586 in Adults With Primary Immune Thrombocytopenia (ITP) (TAI-SHAN11)Phase 2 · Dizal Pharmaceuticals
- Sep 2027DZD8586 in Patients With Relapsed or Refractory CLL/SLL (TAI-SHAN8)Phase 2 · Dizal Pharmaceuticals
Studies
Open first, then newest update. How each study uses birelentinib is read from its arms, and is right about nine times in ten. Ask us to read each study. These are the studies that list it as an intervention; a search of ClinicalTrials.gov also finds studies that mention it only in a description, such as earlier treatment.
Testing it · 12
- Assessing the Effect of a Proton Pump Inhibitor on the Pharmacokinetics of DZD8586 in Healthy Participants (TAI-SHAN21)RecruitingPhase 1Dizal PharmaceuticalsNCT07888569Written as DZD8586
- Birelentinib Plus R-CHOP in Patients With Newly Diagnosed Diffuse Large B-Cell Lymphoma (TAI-SHAN19)Not yet recruitingPhase 2/3Dizal PharmaceuticalsNCT07712588Written as Birelentinib
- A Study of DZD8586 Combination in CLL/SLL (TAI-SHAN10)RecruitingPhase 2Dizal PharmaceuticalsNCT07154264Written as DZD8586
- A Study of DZD8586 Versus Investigator's Choice in r/r CLL/SLL (TAI-SHAN6)RecruitingPhase 3Dizal PharmaceuticalsNCT07139873Written as DZD8586
- DZD8586 in Patients With Relapsed or Refractory CLL/SLL (TAI-SHAN8)RecruitingPhase 2Dizal PharmaceuticalsNCT06539182Written as DZD8586
- DZD8586 Combination Therapy in Patients With Diffuse Large B-cell Lymphoma (TAI-SHAN12)RecruitingPhase 1/2Dizal PharmaceuticalsNCT07059650Written as DZD8586+R-CHOP
- A Study of DZD8586 in Adults With Primary Immune Thrombocytopenia (ITP) (TAI-SHAN11)RecruitingPhase 2Dizal PharmaceuticalsNCT07294365Written as DZD8586 dose level 1
- DZD8586 in Patients With Relapsed or Refractory Diffuse Large B-cell Lymphoma (TAI-SHAN9)CompletedPhase 2Dizal PharmaceuticalsNCT06539195Written as DZD8586
- DZD8586 in Patients With Relapsed or Refractory B-cell Non-Hodgkin LymphomaCompletedPhase 1Dizal PharmaceuticalsNCT05824585Written as DZD8586
- A Mass Balance Study of DZD8586 in Healthy Male Participants (TAI-SHAN15)CompletedPhase 1Dizal PharmaceuticalsNCT07454863Written as DZD8586
- A Study of DZD8586 in Relapsed or Refractory B-Cell Non-Hodgkin Lymphoma (TAI-SHAN1)CompletedPhase 1/2Dizal PharmaceuticalsNCT05844956Written as DZD8586
- A Phase 1 Study to Assess the Safety, Tolerability, Pharmacokinetics of DZD8586 in Healthy Adult ParticipantsCompletedPhase 1Dizal (Jiangsu) Pharmaceutical Co., Ltd.NCT05176873Written as DZD8586
What changed recently
From the registry's own updates since Oct 18, 2026.
Started recruiting1
Newly registered1
Codes
What other systems call birelentinib · ClinicalTrials.gg INT018643
- UNII (FDA) Z2F599L9GDBIRELENTINIBConfirmed FDA, Wikidata
- Wikidata Q140528727birelentinibConfirmed FDA, Wikidata
- NCI Thesaurus C215277BirelentinibOne source FDA
| System | Code | Name there | Checked by |
|---|---|---|---|
| UNII (FDA) | Z2F599L9GD | BIRELENTINIB | Confirmed FDA, Wikidata |
| Wikidata | Q140528727 | birelentinib | Confirmed FDA, Wikidata |
| NCI Thesaurus | C215277 | Birelentinib | One source FDA |
“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.